Prothena Corporation plc (NASDAQ:PRTA) is set to announce third quarter earning results on Wednesday 4th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, PRTA to report 3Q20 loss of $ 0.65 per share.
For the full year, analysts anticipate top line of $ 21.73 million, while looking forward to loss of $ 2.1 per share bottom line.
Previous Quarter Performance
Prothena Corporation plc unwinded loss for the second quarter of $ 0.66 per share, from the revenue of $ 0.20 million. According to street consensus, PRTA was expected to report 2Q20 loss of $ 0.61 per share from revenue of $ 0.15 million. The bottom line results missed street analysts by $ 0.05 or 8.2 percent, at the same time, top line results outshined analysts by $ 0.05 million or 33.33 percent.
Stock Performance
Shares of Prothena Corporation plc traded up $ 0.33 or 2.99 percent on Tuesday, reaching $ 11.36 with volume of 169.10 thousand shares. Prothena Corporation plc has traded high as $ 11.36 and has cracked $ 10.78 on the downward trend
According to the previous trading day, closing price of $ 11.36, representing a 55.35 % increase from the 52 week low of $ 7.10 and a 37.44 % decrease over the 52 week high of $ 17.63.
The company has a market capital of $ 453.39 million and is part of the Healthcare sector and Biotechnology industry.
Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinsons disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimers disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta, a protein for the treatment of Alzheimers disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration.
